Posted by Michael Wonder on 11 Jan 2021
Roche’s Xofluza approved by the European Commission for the treatment of influenza, the first new influenza antiviral for patients in almost 20 years
11 January 2021 - The European Commission has approved single-dose, oral Xofluza for the treatment of uncomplicated influenza in patients aged 12 years and above.
Roche today announced that the European Commission has approved Xofluza (baloxavir marboxil) for the treatment of uncomplicated influenza in patients aged 12 years and above.
In addition, the European Commission has approved Xofluza for post-exposure prophylaxis of influenza in individuals aged 12 years and above. Post-exposure prophylaxis aims to prevent influenza in individuals following contact with someone infected with the influenza virus.
